^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    pan-AKT inhibitor

    Related drugs:
    Apply
    Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (NCT04060394)
    Phase 1/2
    Laekna Limited
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    09/13/2019
    Primary completion :
    12/27/2023
    Completion :
    10/30/2024
    PIK3CA • PTEN • BRCA
    |
    PTEN mutation • BRCA mutation
    |
    docetaxel • prednisone • afuresertib (LAE002) • LAE001
    Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) (NCT04374630)
    Phase 2
    Laekna Limited
    Active, not recruiting
    Last update posted :
    03/13/2024
    Initiation :
    06/09/2020
    Primary completion :
    07/31/2023
    Completion :
    06/28/2024
    BRCA1 • BRCA2 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • PTEN mutation
    |
    paclitaxel • afuresertib (LAE002)
    PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (NCT05390710)
    Phase 1
    Laekna Limited
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    06/12/2021
    Primary completion :
    12/11/2023
    Completion :
    12/11/2023
    HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K
    |
    PD-L1 expression • PGR expression
    |
    albumin-bound paclitaxel • afuresertib (LAE002) • LAE005
    Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 (NCT05383482)
    Phase 1/2
    Laekna Limited
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    06/30/2022
    Primary completion :
    08/31/2024
    Completion :
    12/31/2025
    HER-2 • KRAS • ALK • PTEN • PI3K
    |
    ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative
    |
    docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)
    Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer (NCT04851613)
    Phase 1
    Laekna LLC
    Active, not recruiting
    Last update posted :
    06/07/2023
    Initiation :
    02/18/2022
    Primary completion :
    04/27/2023
    Completion :
    12/30/2024
    HER-2 • PIK3CA • PTEN
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    fulvestrant • afuresertib (LAE002)
    Dose-finding Study in Platinum-Resistant Ovarian Cancer (NCT01653912)
    Phase 1/2
    Accenture
    Completed
    Last update posted :
    04/02/2018
    Initiation :
    11/01/2012
    Primary completion :
    07/01/2015
    Completion :
    11/01/2015
    MUC16
    |
    carboplatin • paclitaxel • afuresertib (LAE002)
    A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers (NCT01476137)
    Phase 1/2
    GlaxoSmithKline
    Completed
    Last update posted :
    11/13/2017
    Initiation :
    10/26/2011
    Primary completion :
    03/12/2013
    Completion :
    03/12/2013
    HER-2 • KRAS • ER • PGR
    |
    KRAS mutation • HER-2 negative
    |
    Mekinist (trametinib) • afuresertib (LAE002)
    Study of Afuresertib Combined With Paclitaxel in Gastric Cancer (NCT02240212)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    04/11/2017
    Initiation :
    10/01/2014
    Primary completion :
    02/07/2017
    Completion :
    02/07/2017
    HER-2
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • afuresertib (LAE002)